Xencor Is Picking Up Analyst Support

Xencor is down some 7% in early trading today, but analysts are telling an increasingly positive story on this name

It appears that ‘Tier 4’ biotech…

Piper Jaffray – April 26th – Reissues Overweight rating and $46 price target

Comments

Stories

Fresh Conversations